The National Health Surveillance Agency (Anvisa) gave a positive opinion on ICodec, the weekly insulin of the Ozepic manufacturer. The information was released firsthand to the vehicles present at the company’s press conference, held on Thursday (6).
There are still no details on the indicated use of the drug by the agency, which should be shared early next week. After this disclosure, the process of pricing medication in Brazil begins, which is conducted by the Chamber of Regulation of the Medicines Market (CMED).
So far, Anvisa has approved drugs from Novo Nordisk for the treatment of obesity in adults and adolescents over 12 years: Saxenda, whose active ingredient is 3 mg liraglute, and Wegovy, which contains 2.4 mg.
Read more:
According to Priscilla Mattar, vice president of the new Nordisk medical area in Brazil, the company’s weekly insulin, which is already used in countries such as Canada, Japan, Australia and Germany, was approved last Wednesday of Ashes (5).
Mattar highlighted the effectiveness of the medication, especially for patients with type 2 diabetes. “With the use of weekly insulin, the risk of hypoglycemia was even lower,” he said.
Continues after advertising
According to the executive, weekly insulin may encourage patients with type 2 diabetes, who fear starting treatment due to fear of daily injections, not postponing the beginning of the care of their condition.
The company has classified the novelty as a significant advance, as Brazil is the third largest sales market in Novo Nordisk.
Mattar also mentioned that there is a study on the use of Wegovy for the treatment of obesity in children aged 6 to 12, but is not yet fit for approval.
Continues after advertising
In addition, the company is developing a new product with state -of -the -art technology that can revolutionize the market: high sensitivity insulin, which would be released into the patient’s bloodstream only when a glucose peak was identified. According to Mattar, “the product is in a very initial phase of clinical tests” abroad.
Obesity Prevention Initiatives
Patricia Byington, Sustainability Manager at Novo Nordisk in Brazil, presented the pharmaceutical project for the prevention of childhood obesity, which is underway in six cities, with Campinas (SP) being the Brazilian representative.
Currently, in partnership with the City Hall, Novo Nordisk is developing strategies aimed at primary prevention of childhood obesity, which will involve multidisciplinary, health and educational approaches.
Continues after advertising
Byington emphasized the importance of obesity prevention, which is directly related to the incidence of cardiovascular disease and diabetes.
